Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)

In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy. Key topics discussed included:The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategiesThe role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myelomaTreatment selection based on patient age, prior therapy, drug exposure, and disease biologyThe importance of shared decision-making and incorporating patient preferences into treatment planningRecent clinical trial data and emerging therapies shaping the future of multiple myeloma careThis episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape. Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media:X/Twitter: https://x.com/oncbrothers⁠Instagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/  Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology.#MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology